Secondary analysis of TAPIS (1307 thrombolysed moderate stroke patients): ticagrelor-aspirin vs placebo gave mRS 0–1 at 90 days in 64.4% vs 53.4% with multiple acute infarcts and 71.2% vs 67.1% without, but the interaction was not significant (P=0.18).
Secondary analysisn = 1,307
Zi et al. Ticagrelor-Aspirin With Thrombolysis by Infarct Patterns in Moderate Ischemic Stroke: TAPIS Subgroup Analysis